Trace Amine-Associated Receptor 1 Regulation of Methamphetamine Intake and Aversion

Total Page:16

File Type:pdf, Size:1020Kb

Trace Amine-Associated Receptor 1 Regulation of Methamphetamine Intake and Aversion TITLE AND INDEX TRACE AMINE-ASSOCIATED RECEPTOR 1 REGULATION OF METHAMPHETAMINE INTAKE AND AVERSION By JOHN H. HARKNESS A DISSERTATION Presented to the Department of Behavioral Neuroscience and the Oregon Health & Science University School of Medicine in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy September 2015 TABLE OF CONTENTS LIST OF FIGURES v LIST OF TABLES vii LIST OF ABBREVIATIONS viii ACKNOWLEDGEMENTS xiii ABSTRACT xv CHAPTER 1: General Introduction 1 History of Methamphetamine Use 1 Methamphetamine as a Drug of Abuse 1 Impact on Health and Communities 4 Current Therapies for Methamphetamine Abuse 5 Pharmacology of Methamphetamine 8 Pharmacokinetics 9 Absorption and Distribution 9 Metabolism and Excretion 11 Pharmacodynamics 12 Actions at Monoamine transporters 12 Trace Amine-Associated Receptor 1 (TAAR1) 13 Factors Mediating Methamphetamine Addiction 18 Adaptations to the Basal Ganglia Reward Pathway 18 Positive and Negative Subjective Effects of 20 Methamphetamine i Physiological Effects 22 Stress Axis Activation 22 Thermal Effects 24 Genetic Influences in Drug Use Behavior 25 Forward and Reverse Genetic Approaches 26 Quantitative Traits 28 QTL Mapping Populations 31 Crosses Derived from Inbred Strains 31 Selective Bred Lines 34 The High and Low MA Drinking (MADR) 39 Selected Lines Methods to Study Drug Effects in Animals 41 Two-Bottle Choice Drinking 42 Self-Administration 45 Conditioned Place Preference and Place 46 Aversion Conditioned Taste Aversion 50 QTL Mapping and Gene Expression Analysis in the MADR 51 Lines Taar1 Knockout Mice 53 Experimental Goals and Hypotheses 55 ii CHAPTER 2: Trace Amine-Associated Receptor 1 Regulation of 58 Methamphetamine Intake and Related Traits CHAPTER 3: Trace Amine-Associated Receptor 1 and Stress 94 Axis Regulation of Methamphetamine Intake CHAPTER 4: General Discussion 139 Goals and Hypotheses 139 Main Findings 140 Responses to Methamphetamine in MADR Mice 145 Methamphetamine Consumption 153 Taste Perception in Methamphetamine Consumption 154 Cognitive, Impulsivity, and Anxiety-like Traits in 156 Methamphetamine Consumption Methamphetamine Reward 159 Methamphetamine Stimulation 163 Methamphetamine Aversion 165 TAAR1-Associated Methamphetamine Effects 167 Thermal Effects 167 Stress Axis Response to Methamphetamine 169 MADR Line Responses to Cocaine and Ethanol 170 Gene Expression Differences in the MADR Lines 172 iii Monoamine and TAAR1 Systems in 176 Methamphetamine Intake NET and SERT in Aversive Effects of 178 Methamphetamine Considerations of the Genetic Models 179 Summary and Conclusions 182 Future Directions 186 REFERENCES 189 iv LIST OF FIGURES Figure 1.1: Proposed mechanism of action for TAAR1 regulation of 16 monoamine activity following MA exposure. Figure 2.1: A quantitative trait locus (QTL) on mouse chromosome 64 10 has a major effect on MA drinking in MADR mice. Figure 2.2: Schematic transmembrane topology of mouse TAAR1 75 and frequency of B6- and D2-like Taar1 alleles in MALDR and MAHDR mice. Figure 2.3: MA consumption and sensitivity to MA-induced CTA 77 differs by Taar1 genotype Figure 2.4: MA- and ethanol-induced hypothermia differs by Taar1 81 genotype. Figure 2.5: The effect of MA on body temperature differs in 84 replicate 3 MAHDR and MALDR mice. Figure 2.6: Function and expression of B6-like and D2-like 86 isoforms of TAAR1 in Taar1- transfected cells. Figure 3.1: Plasma ACTH and CORT difference values from saline 110 baseline after administration of several doses of MA. Figure 3.2: Plasma CORT difference values from saline baseline 112 60 minutes after administration of 2 mg/kg MA in MADR and TAAR1 transgenic mice. v Figure 3.3: MA consumption over days by 116 MAHDR mice offered MA in solution with corticosterone. Figure 3.4: MA preference vs. water over days by MAHDR mice 118 offered MA in solution with CORT. Figure 3.5: Plasma CORT levels 8 h after consuming water, CORT, MA or MA+CORT in MAHDR mice. 120 Figure 3.6: NISX-induced CTA in MAHDR and MALDR mice. 124 Figure 3.7: FLUX-induced CTA between the MADR lines. 126 Figure 3.8: Repeated treatment with NISX prior to MA-induced CTA in the MADR lines. 128 Figure 3.9: Repeated treatment with FLUX prior to MA-induced CTA between the MADR lines. 129 Figure 4.1: Venn diagram of MA-related traits presented in Chapters 2 and 3, organized by mouse line. 184 vi LIST OF TABLES 142 Table 4.1: Summary of Current Results Table 4.2: Summary of Previous Findings in MADR Lines and 146 Progenitor Strains vii LIST OF ABBREVIATIONS +/+ – wildtype genotype CeA – central amygdala +/- – heterozygous genotype cM – centimorgan -/- – knockout genotype Cmax – maximum (peak) plasma 5-HT – serotonin concentration 5-HT1A – serotonin receptor 1A CNS – central nervous system 5-HT1B – serotonin receptor 1B CORT – corticosterone ACTH – adrenocorticotropin CPA – conditioned place aversion hormone CPP – conditioned place preference ANOVA – analysis of variance CRF – corticotropin-releasing factor Ar – androgen receptor gene CS+ – conditioned positive stimulus B6 – C57BL6/J CS- – conditioned negative stimulus B6D2F2 – F2 generation of C57BL/6J and DBA/2J cross CTA - conditioned taste aversion BCA – bicinchoninic acid D1 – receptors bp – base pair D2 – receptors BXD – C57BL/6J and DBA/2J D3 – receptors recombinant inbred line(s) D2 – DBA/2J cAMP –3'-5'-cyclic adenosine monophosphate DA – dopamine Casp8 – caspase 8, apoptosis- DAT – dopamine transporter related cysteine peptidase gene viii d-isomer – dextrorotatory isomer Fos – FOS gene dl – deciliter GABA – γ-aminobutyric acid DMSO – dimethyl sulfoxide GFP – green fluorescent protein EC50 – half maximal effective GLU – glutamate concentration Grm4 – metabotropic glutamate EIA – enzyme Immunoassay receptor 4 gene ELISA – enzyme-linked H2 – heritability immunosorbent assay HIV – human immunodeficiency ES – embryonic stem virus Esr1 – estrogen receptor 1 gene Hivep2 – human immunodeficiency virus type 1 enhancer binding Esr2 – estrogen receptor 2 gene protein 2 gene EtOH – ethanol h – hour EPPTB – N-(3-Ethoxy-phenyl)-4- HMACT - high methamphetamine pyrrolidin-1-yl-3-trifluoromethyl- activation benzamide HPA – hypothalamic-pituitary- adrenal axis eQTL – expression quantitative trait locus Hsce70 – immunoglobulin heavy chain binding protein 70 gene F – female Hsp40 – heat shock protein 40 gene F2 – second filial generation offspring Htr3 – serotonin receptor 3 gene FCS – fetal calf serum Il6 – interleukin 6 gene FLUX – fluoxetine i.p. – intraperitoneal ix i.v. – intravenous MALSENS – methamphetamine low sensitization mouse line KCl – potassium chloride Map3k5 – mitogen-activated protein kg – kilogram kinase kinase kinase 5 gene KO – knockout Mapk3 – ERK-1 MAP kinase gene l – liter Mb – mega base LC – locus coeruleus MDMA – 3,4-methylenedioxy- methamphetamine LiCl – lithium chloride µg – microgram l-isomer – levorotatory isomer mg – milligram LMACT – low methamphetamine activation mg/kg – milligram per kilogram LOD – log of the odds mGlur1 – metabotropic glutamate receptor 1 gene M – male Mpdz – multiple PDZ domain protein MA – methamphetamine gene MADR – methamphetamine drinking mPFC – medial prefrontal cortex mouse lines NAcc – nucleus accumbens MAHDR – methamphetamine high drinking mouse line NaCl – sodium chloride MAHSENS – methamphetamine NE - norepinephrine high sensitization mouse line NET – norepinephrine transporter MALDR – methamphetamine low drinking mouse line NIDA – National Institute on Drug Abuse x NISX – nisoxetine QTG – quantitative trait gene nM – nanomolar QTL – quantitative trait locus NFκB – nuclear factor of kappa light Rela – NFκB subunit p65 gene polypeptide Rep – replicate Nfkb1 – nuclear factor of kappa light polypeptide gene enhancer in B- RI – recombinant inbred cells 1 gene RIPA – radioimmunoprecipitation Nfkb2 – nuclear factor of kappa light assay buffer polypeptide gene enhancer in B- cells 2 gene SA – self-administration NTS – nucleus of the solitary tract SEM – standard error of the mean Oprm1 – µ opioid receptor gene SERT – serotonin transporter PCR – polymerase chain reaction Slc6a2 – NET gene PFC – prefrontal cortex Slc6a4 – SERT gene pg – picogram SNP – single nucleotide polymorphism PKA – protein kinase A Τ – circadian free-running period PKC – protein kinase C T0AM – thyronamine POMC – proopiomelanocortin T1AM – 3-iodothyronamine PVN –paraventricular nucleus of the hypothalamus Taar1 – gene encoding trace amine- associated receptor 1 qPCR – quantitative polymerase chain reaction xi TAAR1 – trace amine-associated receptor 1 UNODC – United Nations Office on Drugs and Crime US – unconditioned stimulus VAPORHCS – Veterans Affairs Portland Health Care System VMAT2 – vesicular monoamine transporter 2 VMB – ventral midbrain WHO – World Health Organization WT – wildtype UCP – uncoupling protein UCP1 – uncoupling protein 1 UCP3 – uncoupling protein xii ACKNOWLEDGMENTS I am grateful to have been surrounded by many brilliant and inquisitive minds throughout my journey to this point. These people instilled in me a sense of curiosity and discovery that makes me hungry to explore and push boundaries. I attribute many of my successes to their support and influence. My mom, dad, and brother encouraged me without reservation, even when the path was hard or uncertain. They taught me to investigate and challenge the world around me, and pushed me to jump from the highest rock, but only after checking the depth of the water. Together, my family has shown me unconditional love and support for which I am forever grateful. I would also
Recommended publications
  • Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms
    Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms Volume 16, Issue 6 December 2001 EDITORIAL Pebbles of Truth 515 Martin Zatz FEATURE Review Clockless Yeast and the Gears of the Clock: How Do They Mesh? 516 Ruben Baler ARTICLES Resetting of the Circadian Clock by Phytochromes 523 and Cryptochromes in Arabidopsis Marcelo J. Yanovsky, M. Agustina Mazzella, Garry C. Whitelam, and Jorge J. Casal Distinct Pharmacological Mechanisms Leading to c-fos 531 Gene Expression in the Fetal Suprachiasmatic Nucleus Lauren P. Shearman and David R. Weaver Daily Novel Wheel Running Reorganizes and 541 Splits Hamster Circadian Activity Rhythms Michael R. Gorman and Theresa M. Lee Temporal Reorganization of the Suprachiasmatic Nuclei 552 in Hamsters with Split Circadian Rhythms Michael R. Gorman, Steven M. Yellon, and Theresa M. Lee Light-Induced Resetting of the Circadian Pacemaker: 564 Quantitative Analysis of Transient versus Steady-State Phase Shifts Kazuto Watanabe, Tom Deboer, and Johanna H. Meijer Temperature Cycles Induce a Bimodal Activity Pattern in Ruin Lizards: 574 Masking or Clock-Controlled Event? A Seasonal Problem Augusto Foà and Cristiano Bertolucci LETTER Persistence of Masking Responses to Light in Mice Lacking Rods and Cones 585 N. Mrosovsky, Robert J. Lucas, and Russell G. Foster MEETING Eighth Meeting of the Society for Research on Biological Rythms 588 Index 589 Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms EDITOR-IN-CHIEF Martin Zatz FEATURES EDITORS ASSOCIATE EDITORS Larry Morin Michael Hastings SUNY, Stony Brook University of Cambridge Anna Wirz-Justice Ken-Ichi Honma University of Basel Hokkaido Univ School Medicine Michael Young Rockefeller University EDITORIAL BOARD Josephine Arendt Terry Page University of Surrey Vanderbilt University Charles A.
    [Show full text]
  • Pipeline of Medications to Treat Substance Use Disorders
    Pipeline of Medications to Treat Substance Use Disorders Iván D. Montoya, M.D., M.P.H. Clinical Director and Deputy Director Division of Therapeutics and Medical Consequences NIDA • Cocaine Outline • Methamphetamine • Cannabis Past-Year Prevalence Per 1,000 1,000 People Per NSDUH, 2018 Past-Year Prevalence Per 1,000 1,000 People Per NSDUH, 2018 Number of Overdose Deaths CDC, 2018 Molecular Neurobiology of Stimulant Use Disorders Glutamate Enkephalin or Excitatory Input Dynorphin Inhibitory Neuron k Opioid Dopamine Receptors Enkephalin Receptors Inhibitory Dopamine Neuron GABA Neuron Neuron m Opioid REWARD Receptors GABA-A Receptors GABA Inhibitory Feedback GABA Presynaptic Inhibitory Opioid Neuron Receptors (m, d?) Ventral Tegmental Area Nucleus Accumbens (VTA) (NAc) Adapted from Koop, 2016 • 5HT2c Agonist - Lorcaserin (Belviq XR®) • Orexin 1 antagonists Cocaine • EMB-101 (Oxazepam + Metyrapone) • Buprenorphine + Opioid Antagonist – Clinical Studies • Ketamine • Oxytocin • L-Tetrahydropalmatine (L-THP) 5-HT2C Agonist - Lorcaserin • Clinically available • Selective agonist • Modulate mesolimbic dopamine, decreasing dopamine release • FDA-approved for weight loss • Lorcaserin (Belviq®)10 mg bid • Lorcaserin XR (Belviq XR®) 20 mg qd • Schedule IV • Arena Pharmaceuticals - Eisai Inc. Lorcaserin Pre-clinical Studies - Stimulants • Decrease cocaine self-administration and the reinstatement of responding for cocaine (Grottick et al., 2000; Burmeister et al., 2004; Burbassi and Cervo 2008; Cunningham et al., 2011; Manvich et al., 2012; RüediBettschen
    [Show full text]
  • Impact of Using Organic Yeast in the Fermentation Process of Wine
    processes Article Impact of Using Organic Yeast in the Fermentation Process of Wine Balázs Nagy 1, Zsuzsanna Varga 2,Réka Matolcsi 1, Nikolett Kellner 1 , Áron Szövényi 1 and Diána Nyitrainé Sárdy 1,* 1 Faculty of Horticultural Science Department of Oenology, Szent István University, 1118 Budapest, Hungary; [email protected] (B.N.); [email protected] (R.M.); [email protected] (N.K.); [email protected] (Á.S.) 2 Faculty of Horticultural Science Department of Viticulture, Szent István University, 1118 Budapest, Hungary; [email protected] * Correspondence: [email protected] Abstract: The aim of this study was to find out what kind of “Bianca” wine could be produced when using organic yeast, what are the dynamics of the resulting alcoholic fermentation, and whether this method is suitable for industrial production as well. Due to the stricter rules and regulations, as well as the limited amount and selection of the permitted chemicals, resistant, also known as interspecific or innovative grape varieties, can be the ideal basic materials of alternative cultivation technologies. Well-designed analytical and organoleptic results have to provide the scientific background of resistant varieties, as these cultivars and their environmentally friendly cultivation techniques could be the raw materials of the future. The role of the yeast in wine production is crucial. We fermented wines from the “Bianca” juice samples three times where model chemical solutions were applied. In our research, we aimed to find out how organic yeast influenced the biogenic amine formation of three important compounds: histamine, tyramine, and serotonin. The main results of this study showed that all the problematic values (e.g., histamine) were under the critical limit (1 g/L), although the organic samples resulted in a significantly higher level than the control wines.
    [Show full text]
  • A Guide to Glutamate Receptors
    A guide to glutamate receptors 1 Contents Glutamate receptors . 4 Ionotropic glutamate receptors . 4 - Structure ........................................................................................................... 4 - Function ............................................................................................................ 5 - AMPA receptors ................................................................................................. 6 - NMDA receptors ................................................................................................. 6 - Kainate receptors ............................................................................................... 6 Metabotropic glutamate receptors . 8 - Structure ........................................................................................................... 8 - Function ............................................................................................................ 9 - Group I: mGlu1 and mGlu5. .9 - Group II: mGlu2 and mGlu3 ................................................................................. 10 - Group III: mGlu4, mGlu6, mGlu7 and mGlu8 ............................................................ 10 Protocols and webinars . 11 - Protocols ......................................................................................................... 11 - Webinars ......................................................................................................... 12 References and further reading . 13 Excitatory synapse pathway
    [Show full text]
  • A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University, [email protected]
    Grand Valley State University ScholarWorks@GVSU Honors Projects Undergraduate Research and Creative Practice 12-2015 Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University, [email protected] Follow this and additional works at: http://scholarworks.gvsu.edu/honorsprojects Part of the Medicine and Health Sciences Commons Recommended Citation Hilla, Devin, "Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment" (2015). Honors Projects. 570. http://scholarworks.gvsu.edu/honorsprojects/570 This Open Access is brought to you for free and open access by the Undergraduate Research and Creative Practice at ScholarWorks@GVSU. It has been accepted for inclusion in Honors Projects by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. Running Head: EFFECTIVE ADHD TREATMENT 1 Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University Honors Senior Thesis EFFECTIVE ADHD TREATMENT 2 Abstract Much debate exists over the proper course of treatment for individuals with attention- deficit/hyperactivity disorder (ADHD). Stimulant medications, such as methylphenidate (e.g., Ritalin) and amphetamine (e.g., Adderall), have been shown to be effective in managing ADHD symptoms. More recently, non-stimulant medications, such as atomoxetine (e.g., Strattera), clonidine (e.g., Kapvay), and guanfacine (e.g., Intuniv), have provided a pharmacological alternative with potentially lesser side effects than stimulants. Behavioral therapies, like behavioral parent training, behavioral classroom management, and behavioral peer interventions, have shown long-term benefits for children with ADHD; however, the success of the short-term management of ADHD symptoms is not as substantial when compared with stimulant medications.
    [Show full text]
  • Is TAAR1 a Potential Therapeutic Target for Immune Dysregulation In
    Graduate Physical and Life Sciences PhD Pharmacology Abstract ID# 1081 Is TAAR1 a Potential Therapeutic Target for Immune Dysregulation in Drug Abuse? Fleischer, Lisa M; Tamashunas, Nina and Miller, Gregory M Addiction Sciences Laboratory, Northeastern University, Boston MA 02115 Abstract Discovered in 2001, Trace Amine Associated Receptor 1 (TAAR1) is a direct target of Data and Results amphetamine, methamphetamine and MDMA. It is expressed in the brain reward circuity and modulates dopamine transporter function and dopamine neuron firing rates. Newly-developed compounds that specifically target TAAR1 have recently been investigated in animal models In addition to brain, TAAR1 is expressed in immune cells METH promotes PKA and PKC Phosphorylation through TAAR1 as candidate therapeutics for methamphetamine, cocaine and alcohol abuse. These studies • We treated HEK/TAAR1 cells and HEK293 involving classic behavioral measures of drug response, as well as drug self-administration, Rhesus and Human cells with vehicle or METH, with and without strongly implicate TAAR1 as a potential therapeutic target for the treatment of addiction. In activators and inhibitors of PKA and PKC. addition to its central actions, we demonstrated that TAAR1 is upregulated in peripheral blood Cells Lines mononuclear cells (PBMC) and B cells following immune activation, and that subsequent • We performed Western blotting experiments to activation of TAAR1 by methamphetamine stimulates cAMP, similar to the function of measure levels of phospho-PKA and phospho- adenosine A2 receptors which are also present in immune cells and play a critical role in the PKC. immune response. Here, we are investigating the relationship between TAAR1 and the • We found that specific activators of PKA and adenosine A2 receptor at the level of cellular signaling and receptor dimerization.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • Certificate of Analysis
    Print Date: Jan 3rd 2020 Certificate of Analysis www.tocris.com Product Name: EPPTB Catalog No.: 4518 Batch No.: 1 CAS Number: 1110781-88-8 IUPAC Name: N-(3-Ethoxyphenyl)-4-(1-pyrrolidinyl)-3-(trifluoromethyl)benzamide 1. PHYSICAL AND CHEMICAL PROPERTIES Batch Molecular Formula: C20H21F3N2O2 Batch Molecular Weight: 378.39 Physical Appearance: White solid Solubility: DMSO to 100 mM ethanol to 100 mM Storage: Store at +4°C Batch Molecular Structure: 2. ANALYTICAL DATA TLC: Rf = 0.2 (Ethyl acetate:Petroleum ether [4:1]) HPLC: Shows 99.9% purity 1H NMR: Consistent with structure Mass Spectrum: Consistent with structure Microanalysis: Carbon Hydrogen Nitrogen Theoretical 63.48 5.59 7.4 Found 63.37 5.53 7.44 Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use bio-techne.com North America China Europe Middle East Africa Rest of World [email protected] Tel: (800) 343 7475 [email protected] Tel: +44 (0)1235 529449 www.tocris.com/distributors [email protected] Tel: +86 (21) 52380373 Tel:+1 612 379 2956 Print Date: Jan 3rd 2020 Product Information www.tocris.com Product Name: EPPTB Catalog No.: 4518 Batch No.: 1 CAS Number: 1110781-88-8 IUPAC Name: N-(3-Ethoxyphenyl)-4-(1-pyrrolidinyl)-3-(trifluoromethyl)benzamide Description: Storage: Store at +4°C Trace amine 1 (TA ) receptor antagonist/inverse agonist; 1 Solubility & Usage Info: exhibits a higher potency at the mouse TA1 receptor than the rat DMSO to 100 mM and human TA150 receptors (IC values are 27.5, 4539 and 7487 ethanol to 100 mM nM, respectively).
    [Show full text]
  • Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission
    The Journal of Neuroscience, October 14, 2015 • 35(41):14057–14069 • 14057 Neurobiology of Disease Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission Alexandra Alvarsson,1* Xiaoqun Zhang,1* Tiberiu L Stan,1 Nicoletta Schintu,1 Banafsheh Kadkhodaei,2 Mark J. Millan,3 Thomas Perlmann,2,4 and Per Svenningsson1 1Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden, 2Ludwig Institute for Cancer Research, SE-17177 Stockholm, Sweden, 3Pole of Innovation in Neuropsychiatry, Institut de Recherches Servier, Centre de Recherches de Croissy, Paris 87290, France, and 4Department of Cell and Molecular Biology, Karolinska Institutet, SE-17177 Stockholm, Sweden Parkinson’s disease (PD) is a movement disorder characterized by a progressive loss of nigrostriatal dopaminergic neurons. Restoration of dopamine transmission by L-DOPA relieves symptoms of PD but causes dyskinesia. Trace Amine-Associated Receptor 1 (TAAR1) modulates dopaminergic transmission, but its role in experimental Parkinsonism and L-DOPA responses has been neglected. Here, we report that TAAR1 knock-out (KO) mice show a reduced loss of dopaminergic markers in response to intrastriatal 6-OHDA administra- tion compared with wild-type (WT) littermates. In contrast, the TAAR1 agonist RO5166017 aggravated degeneration induced by intra- striatal6-OHDAinWTmice.Subchronic L-DOPAtreatmentofTAAR1KOmiceunilaterallylesionedwith6-OHDAinthemedialforebrain bundle resulted in more pronounced rotational behavior and dyskinesia than in their WT counterparts. The enhanced behavioral sensitization to L-DOPA in TAAR1 KO mice was paralleled by increased phosphorylation of striatal GluA1 subunits of AMPA receptors. Conversely, RO5166017 counteracted both L-DOPA-induced rotation and dyskinesia as well as AMPA receptor phosphorylation.
    [Show full text]
  • The in Vitro Binding Properties of Non-Peptide AT1 Receptor Antagonists
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2002; 5 (1), 75-82 The In Vitro Binding Properties of Non-Peptide AT1 Receptor Antagonists Vanderheyden PML, Fierens FLP, Vauquelin G, Verheijen I Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria REVIEWS Binding of Non-Peptide AT1 Receptor Antagonists J Clin Basic Cardiol 2002; 5: 75 The In Vitro Binding Properties of Non-Peptide AT1 Receptor Antagonists P. M. L. Vanderheyden, I. Verheijen, F. L. P. Fierens, G. Vauquelin A major breakthrough in the development of AT1 receptor antagonists as promising antihypertensive drugs, was the synthe- sis of potent and selective non-peptide antagonists for this receptor. In the present manuscript an overview of the in vitro binding properties of these antagonists is discussed. In particular, CHO cells expressing human AT1 receptors offer a well- defined and efficient experimental system, in which antagonist binding and inhibition of angiotensin II induced responses could be measured. From these studies it appeared that all investigated antagonists were competitive with respect to angiotensin II and bind to a common or overlapping binding site on the receptor. Moreover this model allowed us to describe the mecha- nism by which certain antagonists depress the maximal angiotensin II responsiveness in vascular contraction studies. Insur- mountable inhibition was found to be related to the dissociation rate of the antagonist-AT1 receptor complex. The almost complete (candesartan), partially insurmountable inhibition (irbesartan, EXP3174, valsartan) or surmountable inhibition (losartan), was explained by the ability of the antagonist-receptor complex to adopt a fast and slow reversible state.
    [Show full text]
  • Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
    International Journal of Molecular Sciences Review Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Shenglong Zou and Ujendra Kumar * Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-827-3660; Fax: +1-604-822-3035 Received: 9 February 2018; Accepted: 11 March 2018; Published: 13 March 2018 Abstract: The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids also modulate signal transduction pathways and exert profound effects at peripheral sites. Although cannabinoids have therapeutic potential, their psychoactive effects have largely limited their use in clinical practice. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, focusing on the CB1R and the CNS, with emphasis on recent breakthroughs in the field. We aim to define several potential roles of cannabinoid receptors in the modulation of signaling pathways and in association with several pathophysiological conditions. We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids. Keywords: cannabinoid; endocannabinoid; receptor; signaling; central nervous system 1. Introduction The plant Cannabis sativa, better known as marijuana, has long been used for medical purpose throughout human history.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]